NKTR Stock Overview
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Nektar Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.38 |
| 52 Week High | US$1.75 |
| 52 Week Low | US$0.41 |
| Beta | 0.91 |
| 1 Month Change | 55.39% |
| 3 Month Change | 170.59% |
| 1 Year Change | 72.37% |
| 3 Year Change | -93.19% |
| 5 Year Change | -95.64% |
| Change since IPO | -63.20% |
Recent News & Updates
Recent updates
There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise
Feb 15
Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry
Dec 31Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?
Nov 06Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?
Apr 24Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely
Jan 24Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?
Aug 19Nektar: Time To Abandon Ship
Jul 17Nektar promotes internal executive to CFO role
Jul 01We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully
May 11After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline
Apr 04Analysts Just Made A Major Revision To Their Nektar Therapeutics (NASDAQ:NKTR) Revenue Forecasts
Mar 09Nektar Therapeutics: Beaten Down By 2020
Jan 26We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth
Jan 13Nektar Therapeutics (NASDAQ:NKTR) Analysts Just Trimmed Their Revenue Forecasts By 11%
Dec 09Nektar Therapeutics (NASDAQ:NKTR) Is In A Strong Position To Grow Its Business
Oct 05Nektar Therapeutics' Short Covering Surges By 200% In 2 Weeks
Sep 29Nektar Sends Shot Across Bristol Myers Squibb's Bow With Big Pfizer Collaboration
Sep 23Shareholder Returns
| NKTR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.2% | 0.08% | 1.2% |
| 1Y | 72.4% | 13.2% | 24.9% |
Return vs Industry: NKTR exceeded the US Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: NKTR exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| NKTR volatility | |
|---|---|
| NKTR Average Weekly Movement | 16.6% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NKTR's share price has been volatile over the past 3 months.
Volatility Over Time: NKTR's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 137 | Howard Robin | www.nektar.com |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system’s natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Nektar Therapeutics Fundamentals Summary
| NKTR fundamental statistics | |
|---|---|
| Market cap | US$260.74m |
| Earnings (TTM) | -US$276.06m |
| Revenue (TTM) | US$90.12m |
2.8x
P/S Ratio-0.9x
P/E RatioIs NKTR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NKTR income statement (TTM) | |
|---|---|
| Revenue | US$90.12m |
| Cost of Revenue | US$33.77m |
| Gross Profit | US$56.35m |
| Other Expenses | US$332.41m |
| Earnings | -US$276.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.50 |
| Gross Margin | 62.53% |
| Net Profit Margin | -306.31% |
| Debt/Equity Ratio | 86.0% |
How did NKTR perform over the long term?
See historical performance and comparison